首页|慢性阻塞性肺疾病近年临床研究热点

慢性阻塞性肺疾病近年临床研究热点

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
慢性阻塞性肺疾病(简称慢阻肺)是最常见的慢性呼吸系统疾病,因其致残和致死性而备受关注.近年来对其临床研究取得了诸多重要进展.早期诊断和筛查工具的发展,以及基于肺功能发展轨迹、影像学评估和基因表达特征的多维度分型,为慢阻肺的个体化治疗提供了依据.多组学研究在探索慢阻肺生物标志物方面取得重要突破,有助于深入理解疾病的发病机制和病程发展.吸入药物方案的疗效比较和靶向2型炎症的单克隆抗体疗效研究也在不断推进,以期为慢阻肺患者提供更多针对发病机制的个体化治疗手段.
Clinical research hotspots of chronic obstructive pulmonary disease in recent years
Chronic obstructive pulmonary disease(COPD)is the most common chronic respiratory disease,and has at-tracted much attention because of its disabling and fatal nature.Many important advances in clinical research have been made in recent years.The development of early diagnostic and screening tools,as well as multidimensional phenotyping based on lung function trajectories,quantitative imaging assessments and gene signature,have informed individualized treatment of COPD.Multi-omics studies have made important breakthroughs in exploring biomarkers of COPD,contrib-uting to an in-depth understanding of the pathogenesis and progression of the disease.The comparisons of inhaled drug regimens and the efficacy of monoclonal antibodies targeting type 2 inflammation are also advancing,with a view to providing more individualized treatments for patients with COPD by targeting the pathogenesis of the disease.

Pulmonary disease,chronic obstructiveClinical research hotspotsPhenotypeIndividualized treatment

王凤燕、梁振宇、李雪萍、陈荣昌

展开 >

广州医科大学附属第一医院呼吸与危重症医学科广州呼吸健康研究院国家呼吸系统疾病临床医学研究中心呼吸疾病全国重点实验室,广东广州 510120

深圳市人民医院呼吸与危重症医学科深圳呼吸疾病研究所,广东深圳 518020

肺疾病,慢性阻塞性 临床研究热点 表型 个体化治疗

国家重点研发计划国家自然科学基金国家自然科学基金国家自然科学基金深圳市科创委可持续发展专项呼吸疾病国家重点实验室自主课题

2022YFF0710802822000448227004482170042KCXFZ202002011008256SKLRD-Z-202317

2024

10.6040/j.issn.1671-7554.0.2024.0137

山东大学学报(医学版)
山东大学

山东大学学报(医学版)

CSTPCD北大核心
影响因子：0.841
ISSN：1671-7554
年,卷(期)：2024.62(5)